WEBULL
WebtradeDownload

Is Gilead Sciences (GILD) Fully Valued On Its New HIV And Cancer Drug Approvals?

Simply Wall St · 4d ago

Gilead Sciences (GILD) has drawn fresh investor attention after two recent regulatory decisions. The FDA approved Bixlenvo for virologically suppressed adults with HIV, and the European Commission cleared Trodelvy plus Keytruda for certain metastatic triple-negative breast cancer patients.

These approvals arrive after a strong run in Gilead Sciences' stock, with a 30-day share price return of 15.14% and a year-to-date share price return of 23.29%, alongside a 36.48% 1-year total shareholder return that suggests momentum has been building as investors reassess growth prospects and risk.

Spot fresh momentum stories alongside Gilead Sciences by reviewing a curated set of 50 high quality undervalued stocks. These opportunities combine solid cash flows with balance sheet strength.

Gilead Sciences now has fresh products and a strong presence across HIV and oncology. After a share price that moved sharply higher in recent weeks, the key issue is whether that strength is already fully reflected in today’s valuation.

Most Popular Narrative: 16.8% Overvalued

The most followed narrative on Gilead Sciences compares a fair value of $128.38 with the recent $149.92 share price and frames that gap as meaningful. It focuses heavily on how today’s pipeline and investment phase might influence that difference.

Gilead is transitioning from a "single-franchise HIV company" into a multi-platform biopharma with high-probability growth drivers in lenacapavir and Trodelvy, plus high-upside optionality in cell therapy and immunology. However, temporary earnings headwinds from acquisitions and pipeline build-out mean the market could be weighing short-term losses against that longer-term shift.

Read the complete narrative.

Curious how a company with current losses still lands on that fair value. The narrative leans on revenue expansion, margin repair and a future profit multiple that might surprise you. Want to see exactly which assumptions need to hold up for $128.38 to make sense.

Result: Fair Value of $128.38 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Gilead Sciences still faces two clear swing factors: clinical or regulatory setbacks in its crowded oncology pipeline and slower than expected uptake for new HIV regimens.

Find out about the key risks to this Gilead Sciences narrative.

Another View: What Market Ratios Say About Gilead Sciences

The user narrative flags Gilead Sciences as 16.8% overvalued at a $149.92 share price versus a $128.38 fair value. Our checks using a P/S ratio paint a different picture. At 6.1x P/S, Gilead trades below both the US Biotechs average of 13.1x and peers at 7.4x, and also below a fair ratio of 10.9x. That gap can signal either valuation risk if current optimism fades or opportunity if sentiment shifts closer to that fair ratio. Which story do you think markets will lean toward next?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGS:GILD P/S Ratio as at Sep 2026
NasdaqGS:GILD P/S Ratio as at Sep 2026

Next Steps

Given the mixed signals around Gilead Sciences, it makes sense to look at the full picture yourself and decide how the risk reward trade off stacks up for your portfolio. To weigh both sides before you act, start with these 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Gilead Sciences?

If you stop with Gilead Sciences, you might miss other opportunities. Use the Simply Wall Street Screener to spot different types of stocks that fit your goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.